TransEnterix (NYSE:TRXC) said today that Italy’s Sofar SpA agreed to buy a $5 million stake in lieu of a $10 million milestone payment as the duo amended the $100 million deal for Sofar’s Telelap ALF-X robot-assisted surgery device – now known as Senhance. In September 2015, TransEnterix bought the Senhance technology for $25 million up front and about 15.5 […]
Sofar SpA
TransEnterix puts up $100m for Sofar’s ALF-X robot-assisted surgery device
TransEnterix (NYSE:TRXC) said yesterday that it acquired the Telelap ALF-X robot-assisted surgery device from Italy’s Sofar SpA in a deal worth $99.8 million. The Telelap ALF-X device has CE Mark approval in the European Union for minimally invasive surgery procedures. Research Triangle Park, N.C.-based TransEnterix makes the SurgiBot robot-assisted surgery device. The deal included $25 million in up-front […]